Celltrion Wins Race For High-Concentration Adalimumab
Receives Positive CHMP Opinion For 100mg/ml Biosimilar To Humira
Executive Summary
Celltrion expects to receive the world’s first approval for a high-concentration adalimumab biosimilar rival to Humira, after receiving a positive opinion from the EMA’s CHMP for its CT-P17 candidate.
You may also be interested in...
180 Life Sciences’ Woody Sets Out Vision For Repurposing Anti-TNF Biologics
After 180 Life Sciences recently struck a deal with Korea’s Celltrion to support its work in repurposing off-patent biologics, CEO Jim Woody speaks to Generics Bulletin about what the collaboration means for the company and its next steps.
Alvotech And Stada Gain Second Ever Higher-Strength Adalimumab Nod
Alvotech and Stada are on the verge of gaining the world’s second ever approval for a higher-strength Humira biosimilar, after the EMA’s CHMP endorsed the firms’ adalimumab under the names Hukyndra and Libmyris at its September meeting.
Celltrion Sees Double-Digit Growth In Sales And Profit
South Korea’s Celltrion saw a double-digit jump in sales and operating profit in 2020 based on continued growth for its leading biosimilars. Meanwhile, the company is pursuing its strategy of developing at least one biosimilar annually.